Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in investor meetings at ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ...

The consensus rating for Vanda Pharma is Buy, based on 2 analyst ratings. With an average one-year price target of $20.0, ...

CFO Kevin Moran reported Q1 2025 revenues of $50 million, a 5% increase year-over-year, attributed to Fanapt’s growth. Fanapt net product sales were $23.5 million, and HETLIOZ sales were $20.9 million ...

Vanda Pharmaceuticals (NASDAQ:VNDA) is scheduled to announce Q1 earnings results on Wednesday, May 7th, after market close.

As the WNBA experiences a surge in popularity, the Mystics' latest sponsorship deal reflects the growing value proposition of the league. Health care giant inks naming-rights deal for Mystics ...

Good afternoon, and welcome to the Quarter One 2025 Vanda Pharmaceuticals Incorporated Earnings Conference Call. I am Franz, and I will be the operator assisting you today. All lines have been ...

Vanda Pharmaceuticals reported its financial results for Q1 2025, revealing a revenue of $50 million, which fell short of the $61.02 million forecast. The company also reported a net loss of $29.5 ...

WASHINGTON, May 7, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2025. "Vanda has ...

Fanapt® Q1 2025 total prescriptions (TRx) increased 14% compared to Q1 2024 Fanapt® Q1 2025 new to brand prescriptions (NBRx) increased nearly threefold compared to Q1 2024 Bysanti ...

VANDA PHARMACEUTICALS ($VNDA) posted quarterly earnings results on Wednesday, May 7th. The company reported earnings of -$0.50 per share, beating estimates of -$0.61 ...